Related Experiment Video
Updated: Jun 28, 2026
09:29
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Understanding and treating triple-negative breast cancer
1Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7305, USA.
Oncology (Williston Park, N.Y.)
|November 5, 2008
Summary
Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies. Research explores its unique molecular profile, risk factors, and potential new treatments like PARP inhibitors.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Triple-negative breast cancer (TNBC) lacks estrogen receptor (ER), progesterone receptor (PR), and HER2 expression.
- TNBC exhibits aggressive behavior, distinct metastatic patterns, and limited targeted therapies.
- The majority of TNBC cases present a basal-like molecular profile, often associated with BRCA1 mutations.
Purpose of the Study:
- To summarize the characteristics of triple-negative breast cancer.
- To highlight epidemiological findings and risk factors.
- To discuss current and emerging therapeutic strategies.
Main Methods:
- Review of existing epidemiological and molecular studies on TNBC.
- Analysis of gene expression data to identify molecular profiles.
- Examination of clinical trial data for targeted agents.
Main Results:
- TNBC is prevalent in younger women and those of African descent.
- Distinct risk factor profiles differentiate TNBC from luminal subtypes.
- Early relapse and visceral metastasis, including brain metastasis, are common.
Conclusions:
- TNBC is an aggressive breast cancer subtype with unique characteristics.
- Understanding its molecular profile and epidemiology is crucial for risk assessment.
- Targeted therapies, including EGFR, VEGF, and PARP inhibitors, show promise.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...